Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.
Details